RESEARCH ARTICLE

Transient up-regulation of miR-155-3p by lipopolysaccharide in primary human monocyte-derived macrophages results in RISC incorporation but does not alter TNF expression [version 1; peer review: 3 approved with reservations]

Rachel E. Simmonds 🏛️

1Department of Microbial Sciences, University of Surrey, Guildford, GU2 7XH, UK
2Cytokine and Signal Transduction Laboratory, Kennedy Institute of Rheumatology, London, W6 8LH, UK

Abstract

Background: The innate immune response is a tightly regulated process that reacts rapidly in response to pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS). Evidence is accumulating that microRNAs contribute to this, although few studies have examined the early events that constitute the “primary” response.

Methods: LPS-dependent changes to miRNA expression were studied in primary human monocyte-derived macrophages (1°MDMs). An unbiased screen by microarray was validated by qPCR and a method for the absolute quantitation of miRNAs was also developed, utilising 5’ phosphorylated RNA oligonucleotide templates. RNA immunoprecipitation was performed to explore incorporation of miRNAs into the RNA-induced silencing complex (RISC). The effect of miRNA functional inhibition on TNF expression (mRNA and secretion) was investigated.

Results: Of the 197 miRNAs expressed in 1°MDMs, only five were induced >1.5-fold. The most strongly induced was miR-155-3p, the partner strand to miR-155-5p, which are both derived from the BIC gene (B cell integration cluster, MIR155HG). The abundance of miR-155-3p was induced transiently ~250-fold at 2-4hrs and then returned towards baseline, mirroring the BIC mRNA. Other PAMPs, IL-1β, and TNF caused similar responses. IL-10, NF-κB, and JNK inhibition suppressed these responses, unlike cytokine-suppressing mycolactone. Absolute quantitation showed that miRNA abundance varies widely from donor-to-donor, and showed that miR-155-3p abundance is substantially less than miR-155-5p in unstimulated cells. However, at its peak there were 446-1,113 copies/cell, and miR-155-3p was incorporated into the RISC with an efficiency similar to miR-16-5p and miR-155-5p. Inhibition of neither miRNA affected TNF expression in 1°MDMs, but technical challenges here are noted.

Conclusions: Dynamic regulation of miRNAs during the primary response is rare, with the exception of miR-155-3p, which transiently achieves levels that might have a biological effect. Further work on this candidate would need to overcome the technical challenges of the broad-ranging effects of liposomes on 1°MDMs.
Keywords
miRNAs, miR-155, Toll-like receptor signalling, primary human cells, monocyte-derived macrophages, TNF, mycolactone

Corresponding author: Rachel E. Simmonds (rachel.simmonds@surrey.ac.uk)

Author roles: Simmonds RE: Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by grants from the Wellcome Trust (092744) and the Kennedy Institute Trustees.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Simmonds RE. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Simmonds RE. Transient up-regulation of miR-155-3p by lipopolysaccharide in primary human monocyte-derived macrophages results in RISC incorporation but does not alter TNF expression [version 1; peer review: 3 approved with reservations] Wellcome Open Research 2019, 4:43 (https://doi.org/10.12688/wellcomeopenres.15065.1)

First published: 06 Mar 2019, 4:43 (https://doi.org/10.12688/wellcomeopenres.15065.1)
Introduction
In recent years, microRNAs have emerged as important post-transcriptional regulators of gene expression\(^1\). They are mostly produced first as primary transcripts (pri-miRNAs; usually from pol II-dependent promoters) that are subsequently processed by Drosha to form ~70nt hairpin structures (pre-miRNAs) that have the potential to encode two different miRNAs. The pre-miRNAs are exported from the nucleus, processed further by Dicer into mature miRNAs and loaded into the RNA-induced silencing complex (RISC) to carry out their regulatory functions. The two miRNAs that can be encoded on a pre-miRNA have historically been known as the ‘guide’ and ‘passenger’ strands, with the latter being referred to as the “star” miRNA. Early on, these were thought to be degraded with only the ‘guide’ strand going on to perform gene regulatory functions\(^2\). An increasing body of evidence has revealed this not to be the case, and in miRBase, the public repository for miRNA sequence annotation, the two strands are now referred to as -5p and -3p, indicating whether the miRNA is located at the 5’ or 3’ end of the pre-miRNA\(^3\). This recognises that each form has the potential to play a regulatory role depending on its expression in different cells, or in response to stimuli.

Inflammation is one of the most rapid and tightly regulated processes of the immune response, and includes the activation of cells by pathogen- and damage-associate molecular patterns (PAMPs and DAMPs) that are recognised by pattern recognition receptors (PRRs) including the Toll-like receptors (TLRs)\(^4\). For example, lipopolysaccharide (LPS) is recognised by a complex of TLR4 with CD14 and MD2. Following activation, at least two well-defined signalling pathways are activated, including MyD88-IRAK-4-TRAF6-NFkB and TRIF-TRAF3-IRF3. Several microRNAs are commonly found to be upregulated during disease states involving inflammation\(^5\), and at least two of these (miR-155-5p and miR-146a) are regulated by NFkB, downstream of TLR signalling. Indeed, miR-155 is one of the most intensively studied immune microRNAs\(^6\). This well conserved miRNA is encoded by the non-coding B cell integration cluster (BIC or MIR155HG) gene, which has three exons (in humans) the third of which contains the miR-155 pre-miRNA. Overexpression of BIC causes spontaneous lymphoma in mice\(^7\). On the other hand, BIC knockout causes defects in germ centre formation and Ig class switching, leading to immunocompromise\(^8\). The function of miR-155 as a master switch in inflammation has been extensively reviewed elsewhere\(^5,9\). Briefly, induction of miR-155-5p by inflammatory stimuli including LPS in myeloid cells (monocytes, macrophages and dendritic cells), B and T cells has been widely reported. In myeloid cells many different targets have been identified including SHIP-1, SOCS-1 and Bcl6.

The existence and function of the -3p miRNA for miR-155 has been less intensively studied and is more controversial. While miR-155-3p has been present in miRbase for many years (originally annotated as miR-155\(^8\)), it was Zhou et al. who first described TLR7-dependent induction of both miR-155-5p and miR-155-3p in plasmacytoid dendritic cells\(^10\). It has since been shown to be induced by cytokines (TNF and IL-1β/IFNγ) and TLR3 ligands in astrocytes\(^11\), during LPS stimulation of trophoblasts\(^12\), and during *Mycobacterium tuberculosis* infection of monocyte-derived DCs\(^13\). In murine systems, miR-155-3p has been shown to be upregulated in M1 (LPS and IFNγ) bone marrow-derived macrophages\(^13\), as well as in infiltrating T helper cells in experimental autoimmune encephalomyelitis\(^14\). As well as immune pathways, miR-155-3p has been reported to be regulated in other physiological process, including down-regulation during cardiogenesis from embryonic stem cells\(^15\). It was also identified in a methylated form in mantle cell lymphoma (MCL; an aggressive B-cell non-Hodgkin’s lymphoma), and demethylation resulted in increased expression, revealing tumour suppressing properties\(^16\). Despite this, the TargetScan database\(^17\) includes miR-155-3p as a “not confidently identified miRNA”, suggesting that ~1,000 copies/cell of an miRNA are required for it to have a biological function.

Most of the studies mentioned above, similar to the miRNA field more widely, utilise relative expression of miRNAs using a range of techniques such as q-RTPCR, miRNAseq and/or microarrays that result in finding of fold-changes under different conditions. While such analyses are highly informative, most do not provide information on the abundance of the miRNAs, itself known to vary widely. One way of deriving this information is to perform absolute quantitation of the miRNAs (AQ-miRNA) by PCR; however, there is a lack of specific published protocols describing the methodology. Here, a widely applicable method using 5’ phosphorylated RNA oligonucleotides as the template in two-step miRNA expression assays is described.

This manuscript reports some historical data, in which a miRNA microarray was performed to investigate changes to miRNA abundance during the primary immune response. The rationale was that since cytokines are produced by myeloid cells in an inflammatory “burst” with signalling events and key transcripts being increased transiently, any miRNA involvement in this pathway would also need to be rapid. This revealed the transient upregulation of miR-155-3p during the early stages of the TLR4/LPS response in primary human monocyte-derived macrophages (1°MDM). At its peak, abundance in some donors were estimated to surpass 1,000 copies/cell, in line with expectation for miRNAs with biological function and this was supported by evidence showing that it becomes incorporated into the RISC. Also reported are some of the technical challenges of studying a transiently induced, PAMP responsive, miRNA in 1°MDM which may be of interest to other researchers attempting similar experiments. While neither miR-155-5p nor miR-155-3p could be shown to influence TNF mRNA or secretion by 1°MDM, the data suggest that differential ‘arm selection’ has the potential to play some as yet unidentified role in fine-tuning the inflammatory burst by macrophages.

Methods
Reagents
RPMI 1640 cell culture medium and FBS were from PAA. TLR-grade LPS from *Escherichia coli* was from Sigma Aldrich. Other TLR ligands were: poly(IC), MALP-2, Flagellin and R848 (all from Alexis Biochemicals), and PamCys-Ser(Lys)\(_\text{Cys}\),...
3HCl (PamCys) from Invivogen. Cytokines (M-CSF, GM-CSF, IL-1β, IL-10 and TNF) were from Peprotech. The inhibitors SB203580, PD98059 and SP600125 were from Calbiochem. Cycloheximide (CHX) was from Sigma Aldrich. Mycolactone A/B purified from Mycobacterium ulcerans was a gift from Prof Pamela Small (University of Tennesse). Synthetic mycolactone A/B was a gift from Prof Yoshito Kishi (Harvard University). All reagents were tested for contamination with endotoxin using the limulus amebocyte lysate assay (Lonza) and found to have <0.1 U/ml LPS.

Primary human monocyte-derived macrophages, cell culture, RNA extraction, gene expression assays

Primary human monocytes were obtained from plateletpheresis residues purchased from the North London Blood Transfusion Service. Mononuclear cells were routinely isolated by Ficoll-Hypaque centrifugation followed by elutriation as previously described18,19. Monocyte-derived macrophages (MDMs) were obtained by differentiating the cells for 4 days with 10 ng/ml M-CSF in complete RPMI with 10% FCS but lacking antibiotics. The data in this manuscript was derived from at least 10 independent enrichment and differentiations.

1°MDMs were harvested then re-plated at 1x10⁶ cells/ml and were routinely stimulated with 100 ng/ml LPS. Other TLR ligands were used at different concentrations: poly(I:C); 20 µg/ml, PamCys; 10 ng/ml, MALP-2; 30 ng/ml, Flagellin; 10 ng/ml and R848; 1 µg/ml. All cytokines were used at 10 ng/ml. When used, the final concentration of other inhibitors were SB203580 (p38; 1 µM), PD98059 (ERK, 20 µM), SP600125 (JNK, 10 µM), CHX (translation, 10 µg/ml), and PSi (proteasome inhibitor)/ NFxB, 5 µM were pre-incubated with the cells for 1 hr prior to stimulation. Mycolactone A/B was used a different concentrations depending on its provenance, and at concentrations shown to be induced by LPS. The microarray was performed by Exiqon as a contracted service. Background subtraction used a convolution model; Normexp with offset value 12. Normalisation was by LOWESS regression. Spots where no signal above background was detected were removed.

Method for the absolute quantitation of miRNAs

Relative changes in miRNA abundance were quantified using Taqman miRNA assays (Applied Biosystems) using the following probes: hsa-miR-155; #2623, hsa-miR-155##; #2287, hsa-miR-16; #39. These include a miRNA reverse transcription step to create a miRNA-specific cDNA that also introduces extension sequences that can be used as the template for qPCR in the second step using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). The manufacturer’s recommendations were followed, with 80 ng total RNA as the input. After reverse transcription, 50 µl nuclease water was added, diluting the reactions by 4.3-fold. Subsequent qPCR was performed using an ABI 7900HT instrument in either duplicate or triplicate with a 384-well block and reaction volumes of 10 µl. Each reaction consisted of 4.5 µl of the diluted reverse-transcription reaction, 5 µl of 2x Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems), 0.35 µl of the specific 20x Taqman Assay and 0.15 µl nuclease-free water. Singleplex reactions were used because multiplex reactions were found to significantly alter the ΔCts during the highly dynamic TLR4 response (for example see raw data file 5_171, available on OSF3). Negative controls included separate NTCs for reverse transcription and PCR steps. Cycling conditions were 95°C for 10 minutes then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.

All PCR-based absolute quantification (AQ) approaches involve the amplification of templates at known concentrations in order to form a standard curve based on Ct values. Hence, the AQ-miRNA approach uses synthetic miRNAs (5’ phosphorylated RNA oligonucleotides, Eurofins MWG) as the template for miRNA reverse transcription reactions (see Results). These corresponded to the miRbase sequences of hsa-miR-16-5p, hsa-miR-155-5p and has-miR-155-3p (Table 1). The oligonucleotides were re-suspended in nuclelease-free water at a concentration of 100 pmol/µl (100 pM) and stored at -80°C.

To generate the standard curve, serial dilutions of the synthetic miRNAs were reverse transcribed using the corresponding RT Primer and an input range 0.001–100 fmol/reaction (in 5 µl, giving a total volume of 15 µl). This was achieved by diluting each synthetic miRNA to 20 fmol/µl (0.2 µM) then performing eight 1 in 10 dilutions in nuclease-free water. Due to the extremely
Table 1. Sequences of synthetic miRNAs (5’ phosphorylated RNA oligonucleotides).

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa-miR-155-5p</td>
<td>UUAUGCUAAUUCGUAUAGGGGU</td>
</tr>
<tr>
<td>hsa-miR-155-3p</td>
<td>CUCUCAUUAAUAGCAUAACA</td>
</tr>
<tr>
<td>hsa-miR-16-5p</td>
<td>UAGCGACAGUAAUAUUGGCG</td>
</tr>
</tbody>
</table>

low concentration of miRNAs resulting, the dilutions were made from stocks fresh each occasion. No other alterations were made to the manufacturer’s protocol and test samples were reverse transcribed in parallel with the standard curve. These were either 80 ng total RNA, or 5 µl of the total RNA obtained during RIP (equivalent to 6.25% of the total, see below). Subsequently all standards and test samples were handled in an identical manner, and absolute quantitation was performed on the ABI 7900HT with the same reaction set up as described above.

This analysis gave results with the units “fmol”. For analysis of cellular abundance of a particular miRNA, this equated to fmol/80 ng total RNA. In order to convert this value into copies/cell, the following calculation was performed:

\[
\text{copies/cell} = \frac{\text{fmol in qPCR} \times \text{total average yield RNA} \times 6.02 \times 10^4}{80 \text{ng}} + \text{no of cells}
\]

RNA immunoprecipitation (RIP) of miRNAs loaded in the RISC

In order to determine whether miRNAs were incorporated into the RISC complex following their expression, an RNA immunoprecipitation (RIP) strategy was employed, building on the method of Wang23. Here, approximately 10x10⁶ MDMs were treated, then washed twice on ice with ice-cold PBS then lysed with Ago lysis buffer (ALB) for 10 mins on ice, then centrifuged for 10 mins at 4°C. ALB contained 20 mM Tris (pH 7.5) 200 mM NaCl, 2.5 mM MgCl₂, 0.5% Triton-X-100, 1x protease inhibitor cocktail (Sigma) and 100 U/ml RNasin (Promega) made up in RNase free water.

The supernatant-containing the cytoplasmic fraction was pre-cleared with protein G sepharose beads [pre-treated with 0.5 mg/ml tRNA (Invitrogen) and 1 mg/ml BSA (New England Biolabs) to block non-specific binding sites] for >30 mins. Beads were removed by centrifugation and the supernatant was processed for RIP.

For RIP, precoated Protein G sepharose beads were prepared by incubation with either 2 µl of ascities fluid containing antibodies to human Argonaute proteins (2A8, kind gift of Zissimos Mourelatos, University of Pennsylvania)23 or normal mouse serum (as a control, containing non-relevant IgGs), then blocked with 0.5 mg/ml tRNA and 1 mg/ml BSA, as above. Precoated beads were then incubated with the precleared supernatants for at least 1.5 hours. Beads were then washed twice with ice cold ALB, then three times with high salt/detergent ALB (ALB containing 900 mM NaCl and 1% Triton-X-100), then twice with ALB and finally once with a low-detergent ALB (ALB containing 0.005% Triton-X-100). Finally, the beads were resuspended in 250 µl 1x DNase buffer (Promega) with 200 U/ml RNasin and 0.04 U/ml DNase I and incubated at 37°C for 20 mins. After removal of the supernatant, the beads were either boiled in 1x Gel Sample Buffer for SDS-PAGE and immunoblotting according to standard techniques20, or they were resuspended in 600 µl miRvana Lysis/homogenisation buffer for RNA extraction. For immunoblotting, the primary antibody was 2A8 (diluted 1 in 500), and the secondary was an HRP-conjugate polyclonal goat anti-mouse Ig (RRID AB_2617137) at 1 in 2000.

For miRNA AQ, the formula used to convert fmol to copies/cell was:

\[
\text{copies/cell} = \frac{\text{fmol in qPCR} \times 80 \mu l \times 6.02 \times 10^4}{5 \mu l + \text{no of cells}}
\]

Alternatively, incorporation of miRNAs is estimated as % of input RNA, which eliminated the need for AQ miRNA. Here, 20% of the cell lysates were processed directly for total RNA before proceeding with RIP. Here, the calculation used was:

\[
\text{% input} = 2^{\left[\frac{\text{Ct}_{\text{IP}} - \text{Ct}_{\text{Input}}}{\text{mean}}\right]} \times \frac{100}{20}
\]

Inhibition of miRNAs

Both miR-155-5p and miR-155-3p were inhibited using miRCURY LNA knockdown probes (Exiqon; miR-155-5p, #410077-00; miR-155-3p, #410079-00; negative control Scramble-miR, #199002-00). Oligonucleotides were transfected into macrophages using Dharmafect 1 (DF1, Dharmacon) using a well-optimised method24. Briefly, complexes of oligonucleotides in a 1/50 dilution of DF1 in OmniMEM (Life Technologies) were prepared. Transfections took place in serum-free RPMI with no phenol red to which complexes were added in a final proportion of 75.25%. The recovery time before stimulation was 3.5 hrs, since pilot experiments showed that extending the recovery time to significantly reduced the efficiency of inhibition below a meaningful level. After recovery, media was replaced with complete RPMI, then stimulated with LPS for 2 hrs.

Statistical analysis

Error calculations for technical replicates of qPCR were performed using Microsoft Excel, where the errors is calculated from the combined standard deviation of the ddCt, using the formula SQRT(SUMSQ(SD of housekeeping Cts)+SUMSQ(SD of Gene of Interest Cts)). The minus error adds this value to the ddCt, calculates 2ⁿ, then calculates the difference from the final relative expression. This approach takes into account the non-linear nature of qPCR data. Excel spreadsheets showing this calculation are available on OSF22.
miR-155-5p and miR-155-3p are differentially regulated in primary human monocyte derived macrophages by LPS. Human 1°MDMs were exposed to 100 ng/ml LPS and/or 10 ng/ml IL-10 for different time periods, total RNA was extracted and cell culture supernatants were collected. (A) Control data, showing that the cells had the expected kinetics of TNF mRNA induction and secretion in response to LPS and/or IL-10. N=4. Mean±SEM; paired t-test, *p<0.05. (B) Box plot showing the array data after normalisation. (C) Heat map of the miRvana microarray v.10 showing relative abundance of miRNAs compared to the common reference sample. The top 6 miRNAs up-regulated by LPS at each timepoint as well as miR-146b-3p and miR-766-3p that were up-regulated by IL-10 at 4 hours, as well as miR-16-5p which did not change over the timecourse. (D, E) Validation of miR-155-5p and miR-155-3p by relative expression with Taqman miRNA assays using RNA from the 4 independent human donors that made up the samples for the array. The comparator was miR-16-5p. Mean±SEM; paired t-test, *p<0.05, **p<0.01. (F) Relative changes to the expression of BIC (MIR155HG), miR-155-5p, and miR-155-3p and over time; the endogenous control for the miRNAs was miR-16-5p, for BIC it was GAPDH. Mean±SEM n=5–9.
Figure 2. The effect of cell signalling inhibitors, and the *M. ulcerans* exotoxin mycolactone on the expression of miR-155-5p and miR-155-3p. Human 1°MDMs were pre-incubated in the absence or presence of inhibitors/toxin for 1 hr prior to 4 hrs 100 ng/ml LPS stimulation. Total RNA was extracted and cell culture supernatants were collected. Relative changes to the steady state levels of BIC (MIR155HG), miR-155-5p, and miR-155-3p (A, C) and TNF mRNA (B, D) were quantified; the endogenous control for the miRNAs was miR-16-5p, for BIC and TNF it was GAPDH. Cytokine secretion was assessed by ELISA. (A, B) The effect of different cell signalling inhibitors [SB203580 (p38; 1 µM), PD98059 (ERK, 20 µM), SP600125 (JNK, 10 µM), CHX (inhibitor of translation, 10 µg/ml), and PSI (inhibitor of NFκB pathway, 5 µM)]. Mean±SEM n=3–4; one sample t-test on log₂ transformed data compared to ctrl (LPS stimulated cells without inhibitors) or one-way ANOVA. *p<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (C, D) The effect of mycolactone A/B in different forms (either purified from *M. ulcerans* bacteria “Natural MYC”, or chemically synthesised “Synthetic MYC”). Mean ± error of single donor experiments (see Methods: Statistical analysis).
one-way ANOVA with Bonferroni’s multiple comparison test (when comparing the relative secretion of TNF between equivalent amounts of scrambled vs miRNA specific oligonucleotides). All analyses were carried out using Graphpad Prism v7.04.

Results

Differential regulation, and differential expression of miR-155-5p and miR-155-3p

A miRNA microarray was performed focussing on the primary response to LPS stimulation (TLR4 activation; 2, 4 and 8 hr) in primary human monocyte-derived macrophages (1°MDMs), and the effect of IL-10 co-incubation. The cells used in the array were performed as expected in terms of induction of TNF mRNA and secretion (Figure 1A), and normalised data from the array appears acceptable (Figure 1B). The pooled donor approach used has limitations, so statistical analysis of the microarray data cannot be performed. Therefore, observations that are not supported by detailed validation should be considered cautiously. Of the 719 miRNAs examined, 197 were expressed in 1°MDMs (defined as expression greater than background in all six slides) and the common reference sample, representing cells in all tested conditions, exhibited a wide variation in fluorescence intensities in the array (see “List of miRNA expressed in primary human MDMs”, available on OSF[2]). Over the six slides, the variation in fluorescence intensity of the common reference was 16±4%, suggesting good technical reproducibility. One of the highest expressed miRNAs was miR-16-5p, which was not altered upon exposure of the cells to LPS over the 8-hour time-course of the experiment (Figure 1C). Raw microarray data are available at the Gene Expression omnibus, accession number GSE125572. All other raw data are available on OSF[2].

Only five miRNAs were found to be upregulated >1.5-fold at any time point; miR-155-5p, miR-155-3p, miR-886-5p, miR-886-3p, and miR-147b-3p (Figure 1C) and see “Microarray data for the 197 expressed miRNAs” available on OSF[2]). None were downregulated, neither were any changes in response to 4 hrs stimulation with IL-10 alone (range 0.83–1.36-fold, see “Microarray data for the 197 expressed miRNAs” on OSF[2]). As time increased, more miRNAs were induced. Hence at 2 hrs, only miR-155-5p and miR-155-3p were significantly upregulated >1.5 fold. This increased to four miRNAs (additionally miR-886-5p and miR-886-3p) at 4 hrs, and five (additionally miR-147b-3p) at 8 hrs. The microarray data suggest that IL-10 may both positively and negatively regulate miRNA expression. Compared to 4 hrs with LPS alone, IL-10 increased the expression of miR-766-3p 1.7-fold and miR-146b-3p 2.3-fold, and decreased the expression of miR-155-3p (Figure 1C, see below). Indeed, miR-155-3p was the most strongly upregulated miRNA at any timepoint. Relative expression validation by Taqman miRNA qPCR from four independent human donors showed that, whereas miR-155-5p levels showed a steady increase as expected during the timecourse of the experiment (Figure 1C), miR-155-3p was >100-fold induced at 2 hours, after which the levels began to reduce again (Figure 1D). This unusually large response, along with the interesting kinetics lead to a more detailed investigation of the finding.

Changes to the abundance of pri-miR-155 (i.e. the BIC/MIR155HG mRNA transcript) following exposure of macrophages to LPS were monitored alongside miR-155-5p and miR-155-3p in 10 human donors, taking a more detailed look at either early or later timepoints following stimulation (compiled data, Figure 1E). Here, miR-155-3p induction was found to be remarkably rapid, being detected 20 mins after LPS exposure. Interestingly, this correlates with a small ‘dip’ in the levels of BIC mRNA. Subsequently both miR-155-3p and BIC induction is remarkably similar, peaking at 2–4 hours and returning to close to resting levels at 24 hours. In stark contrast, miR-155-5p expression rises steadily and continues to rise even as BIC mRNA levels begin to subside.

These data may suggest that the biosynthesis of miR-155-5p and miR-1553p have different molecular controls governing their expression. In order to examine the signalling pathways that might be involved in miRNA and BIC induction, small molecule inhibitors of p38, ERK, JNK and the NF-κB pathway were used (Figure 2A–C). All the inhibitors reduced TNF secretion to different extents, as expected (Figure 2B). The 4-hour timepoint was chosen as a suitable time at which upregulation of both miR-155-5p and miR-155-3p would be detectable. However, it should be noted that this is somewhat late in the TNF mRNA response, which peaks at ~1 hr (Figure 3A). This is likely the explanation for the limited effect of p38 and ERK inhibition on TNF mRNA transcription at 4hrs, which could be observed at 1 hr (raw data file 11_005, available on OSF[2]).

Reduction in the abundance of BIC, miR-155-5p and miR-155-3p by IL-10 was confirmed in these experiments (Figure 2A). However, neither the p38 inhibitor SB203580 nor the ERK inhibitor PD98059 significantly influenced induction at 4 hrs. The JNK inhibitor SP600125 decreased expression of all three molecules similarly by around 50%: however, by far the most profound decrease was with PSL, which decreased BIC mRNA and miR-155-5p levels about 5-fold, but miR-155-3p levels about 16-fold, a statistically significant difference. In addition, the translation inhibitor cycloheximide was used to investigate whether BIC was a primary or secondary response gene in MDMs. BIC mRNA was super-induced by cycloheximide, similarly to TNF mRNA in these cells (a well-recognised phenomenon, Figure 2C). However, neither miR-155-3p nor miR-155-5p was significantly changed in these circumstances (Figure 2A). This data suggests that different pathways may exist that control the induction of the BIC transcript, and that there are additional/different signals required for miRNA biogenesis.

The M. ulcerans exotoxin mycolactone is known to be immunosuppressive and strongly inhibit the production of cytokines, including TNF, from monocytes and macrophages due to blockade of Sec61-dependent translocation of proteins into the endoplasmic reticulum. In order to determine whether LPS-dependent induction of miR-155 was a primary or secondary effect due to alteration of cytokine production, we investigated whether it altered the expression of miR-155 isoforms (Figure 2C, D). Mycolactone (either purified from the bacteria or...
Figure 3. Differential regulation of miR-155-5p and miR-155-3p by other TLR ligands and cytokines, and in other myeloid cells. (A, B) Human 1°MDMs were exposed to a range of TLR ligands or cytokines for different time periods and total RNA was extracted and cell culture supernatants were collected. Cytokines were IL-1β and TNF, both at 10 ng/ml. TLR ligands were 10 ng/ml LPS (TLR4); 10 ng/ml, poly(I:C) (TLR3); 20 µg/ml, Pam3Cys(TLR1/2); 10 ng/ml, MALP-2 (TLR2/6); 30 ng/ml, Flagellin (TLR5); 10 ng/ml and R848 (TLR7/8); 1 µg/ml. (C, D) Either primary monocytes or MDMs differentiated with GM-CSF (as opposed to M-CSF) were exposed to LPS for different time periods and total RNA was extracted. (A, C) Relative changes to the steady state levels of TNF mRNA BIC (pri-miRNA-155), miR-155-5p, and miR-155-3p and over time; the endogenous control for the miRNAs was miR-16-5p, for TNF and BIC it was GAPDH. Mean±SD of technical triplicates. (B, D) Cytokines in supernatants were quantified by ELISA.
chemically synthesised) strongly blocked the production of TNF, whilst having a minimal effect on TNF mRNA abundance (Figure 2D), as expected\(^\text{h}\). These experiments only revealed small fluctuations in BIC, miR-155-5p and miR-155-3p (Figure 2C) ruling out secondary pathways.

**BIC, miR-155-5p and miR-155-3p are differentially induced following stimulation by a wide range of proinflammatory cytokines, TLR ligands, and in other primary myeloid cells**

In order to examine whether the differential regulation of the two strands of miR-155 derived from the BIC gene was unique to LPS (TLR4) stimulation of MDM, a wide variety of different TLR ligands were tested over a timecourse in a single human donor. While further repetition would be need to make firmer conclusions, this data suggested that IL-1\(\beta\), TNF, Pam, Cys (TLR1/2), MALP-2 (TLR2/6), Flagellin (TLR5) and R848 (TLR7/8) are all able induce a broadly equivalent upregulation of steady state BIC mRNA abundance over the 4hr timecourse of the experiment (Figure 3A). On the other hand, the TLR3 ligand poly(I:C) only induced a very weak response by BIC despite a robust induction of IP-10 cytokine secretion (downstream of type I interferons, Figure 3B).

Furthermore, the response was not limited to MDMs that had been in vitro differentiated with M-CSF. Primary monocytes, as well as MDMs differentiated with GM-CSF, also induced BIC, although the response from GM-CSF MDMs was lower (Figure 3C). In all cases, perhaps with the exception of poly(I:C), the upregulation of miR-155-3p was more rapid and of a far larger degree than miR-155-5p (Figure 3). In no cases did upregulation of miR-155-3p outstrip that of BIC.

**Absolute quantitation of miRNAs using synthetic miR-16-5p, miR-155-5p and miR-155-3p**

In order to better understand the differential regulation of the two strands of miR-155, an approach was developed that facilitated the absolute quantitation of miRNAs in cells (AQ miRNA, Figure 4A). Since very few specific protocols appear to be available for such an approach, the methodology has been described in detail as a community resource. Examples of the standard curves that resulted from the reverse transcription of synthetic miRNAs are shown in Figure 4B for miR-155-5p, miR-155-3p, and miR-16-5p. This approach routinely resulted in standard curves of high quality, with \(r^2 > 0.99\) in all cases over a large input range (Table 2). The ability of these assays to detect miRNAs differs slightly depending on the miRNA sequence, for instance the detection limit for miR-155-5p and miR-155-3p was 0.001 or 0.0001 fmol, whereas for miR-16-5p it was always 0.0001 fmol. There were also variations in the apparent efficiency for the combined reverse transcription and PCR reactions, which were around 75%, lower than you would expect for qPCR. However, it is important to note that for this is not comparable to the typical PCR efficiency, as it is a two-step assay where the amount of input RNA into reverse transcription was varied. In circumstances where input RNA amounts are, by definition, very low (such as RIP, where RNA is barely detectable by nanodrop, not shown), such a reduction in efficiency should affect the standard and test samples equivalently.

### Table 2. Performance of standards in the assay.

The mean values obtained from \(n=7\) standard curves is shown.

<table>
<thead>
<tr>
<th>miRNA</th>
<th>(r^2)</th>
<th>Slope</th>
<th>Efficiency (RT&amp;PCR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-16-5p</td>
<td>0.9985</td>
<td>-4.127</td>
<td>75.0%</td>
</tr>
<tr>
<td>miR-155-5p</td>
<td>0.9984</td>
<td>-4.137</td>
<td>75.5%</td>
</tr>
<tr>
<td>miR-155-3p</td>
<td>0.9977</td>
<td>-4.050</td>
<td>77.2%</td>
</tr>
</tbody>
</table>

*On several occasions the lowest standard (0.0001fmol synthetic miRNA) did not give amplification above background; in such cases this point was not considered, increasing the detection limit of the assay to 0.001fmol, and the values are calculated from the remaining points.

Absolute quantitation of cellular miRNAs reveals the wide difference in abundance of miRNAs

Using the AQ-miRNA method we found that there are on average ~12,500 copies of miR-16-5p per macrophage (depending on the donor, Figures 4C, summarised in Table 3), whereas resting cells contain ~1,300 copies of miR-155-5p and ~30 copies of miR-155-3p, which rose to an average of ~750 copies/cell at 2 hrs. Hence there is a 400-fold difference in the abundance between miR-16-5p and miR-155-3p in resting cells, but a 16-fold difference after activation.

It seems likely that the variation seen here reflects truly wide donor-to-donor variability. Transforming the fmol/80ng readout of the AQ-miRNA assay into copies/cell also makes a number of assumptions that may contribute to this variation between experiments, such as similar RNA extraction efficiency and cell counting accuracy. However, the prevalence of each miRNA varies independently (for example, the donor displayed in red in Figure 4D had the highest miR-16-5p, intermediate miR-155-5p levels and the lowest miR-155-3p abundance).

Despite its low abundance, miR-155-3p associates with the RISC

One explanation for the low numbers of miR-155-3p molecules per cell is that they are simply an artefact of the large increase in BIC and associated processing of pre-miR-155-5p into miR-155-5p. Such processing would presumably release the passenger strand, which is not incorporated into the RISC, and this might be detectable for a short period before it is degraded. Alternatively, the pre-miRs may be actively processed to result in miR-155-3p loading in the RISC to carry out biological functions.

In order to examine this, the incorporation of miRNAs into the RISC was estimated by enriching them using RIP and antibodies that recognise human Argonaute proteins. Control experiments showed that the approach successfully immunoprecipitated the proteins (Figure 5A); as previously reported there was some cross-reactivity to a non-relevant protein called Radixin\(^\text{i}\). Using this approach, several thousand copies/cell of miR-16-5p were associated with the RISC in both unstimulated and stimulated cells (Figure 5B). Fewer copies of miR-155-5p were detected in this way; several hundred copies/cell in resting cells, which increased in stimulated cells (Figure 5B). Note that at this time-point, there had only been a 3-fold increase in total cellular
Figure 4. Absolute quantitation of miR-16-5p, miR-155-5p and miR-155-3p in primary human monocyte derived macrophages. (A) Schematic showing the approach for absolute quantitation. (B) Examples of standard curves achieved with the method for each of three miRNAs: miR-16-5p, miR-155-5p and miR-155-3p. Mean±SD of triplicate values are shown. (C) Human 1°MDMs were exposed to 100ng/ml LPS for different time periods. Total RNA was extracted and miRNA abundance was estimated using the absolute quantitation method in singleplex. The donor-to-donor variability of miRNA abundance over time, showing the mean and each donor in a different colour. Note that the prevalence of each miRNA varies independently.

Table 3. Copy-numbers per cell of different miRNAs obtained using the absolute quantitation approach. Compiled data from n=4–6 human donors is shown. *For some donors, this was below the lowest detectable standard in the assay.

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Condition</th>
<th>Total copies/cell</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean ± SEM</td>
</tr>
<tr>
<td>miR-16-5p</td>
<td>resting</td>
<td>12,496±1984</td>
</tr>
<tr>
<td></td>
<td>24hrs LPS</td>
<td>11,880±2935</td>
</tr>
<tr>
<td>hsa-miR-155-5p</td>
<td>resting</td>
<td>1,315±417</td>
</tr>
<tr>
<td></td>
<td>24hrs LPS</td>
<td>9,203±4,216</td>
</tr>
<tr>
<td>hsa-miR-155-3p</td>
<td>resting</td>
<td>29±11</td>
</tr>
<tr>
<td></td>
<td>2hrs LPS</td>
<td>767±137</td>
</tr>
<tr>
<td></td>
<td>24hrs LPS</td>
<td>35±29</td>
</tr>
</tbody>
</table>

*For some donors, this was below the lowest detectable standard in the assay.

miR-155-5p (donor shown in pale blue in Figure 4C). Importantly, although miR-155-3p could not be detected within the RISC above background levels in resting cells, following LPS stimulation for 2hrs (the peak of miR-155-3p detection in cells) it could be recovered with similar efficiency (Figure 5B). This was also true when an alternative method for estimating the proportion of miRNAs incorporated into the RISC was used (Figure 5C).

Technical challenges and limitations of assessing miRNA targets in primary human MDM
The primary focus of this study was to investigate whether miRNAs could directly regulate cytokine production in the primary immune response. The rapid induction of miR-155-3p seemed to suggest that this might be the case. To analyse this further, inhibition of miRNAs was achieved using LNA knockdown oligonucleotides that form stable duplexes with both miR-155-5p and miR-155-3p (Figure 6). A timepoint of 2 hrs was chosen for this experiment, taking into account the kinetics of the different
Figure 5. miR-16-5p, miR-155-5p and miR-155-3p may all be loaded into the RISC in primary human monocyte derived macrophages. (A–C) The RISC complex in human 1°MDM was immunoprecipitated using antibodies that recognise Argonaute proteins (2A8) or control sera (ctrl). All data is representative of n=3 independent donors. (A) Western blot analysis of input protein (left panel) or eluted protein (right panel). Note that the antibodies cross-react with a protein called Radixin (*). (B) miRNAs loaded into the RISC were isolated by RIP using 2A8 and control antibodies. RNA isolated from the RISC were subject to absolute quantitation. Mean±SD of triplicate values. (C) miRNAs loaded into the RISC were isolated by RIP using 2A8 and control antibodies. RNA isolated from the RISC were quantified as a proportion of those in the input. Mean±SD of duplicate values. #: both the input and RIP samples for miR-155-3p had Ct values of 35-36, at the detection limit of the PCR.

induced mRNAs being studies; hence, at 2 hrs induction of TNF, BIC, and miR-155-3p are all near their peak and miR-155-5p induction can be detected. A significant challenge here was that the liposomes used for transfection have profound effects on the signalling pathways within cells even in the absence of exogenous DNA. For instance, unstimulated 1°MDMs that had been exposed to liposomes in serum-free medium (but not serum-free medium alone) showed increases in TNF and/or BIC mRNA (Figure 6A), without the production of TNF protein into the media (Figure 6B). This may be due to activation of a type I
Figure 6. No effect of miR-155-5p or miR-155-3p inhibition on the production of TNF by primary human MDMs. Human 1° MDMs were transfected with miRcury LNA miRNA knockdown probes (either the negative control Scramble-miR, scr, or miR-155-5p or miR-155-3p) using Dharmafect 1. Duplicate 2 hr transfections were performed and one set of cells were stimulated with LPS for 2 hrs, while the unstimulated rested for an additional 2 hrs. Supernatants were collected for the measurement of secreted cytokines and total RNA was extracted. (A) Abundance of TNF, BIC and IFIT1 mRNA by fold-change in unstimulated control cells, compared to cells alone stimulated with LPS (comparator; GAPDH). Each dot is the mean of technical triplicates from qPCR. (B) TNF secretion from unstimulated control cells, compared to cells alone stimulated with 100 ng/ml LPS. Each dot is the mean of technical duplicate from ELISA. (C) Efficiency of “knockdown” was assessed by relative abundance of miRNAs in LPS-stimulated cells (comparator; miR-16-5p). Mean±SEM, n=2–4. (D) Relative abundance of TNF mRNA and secreted protein in the LPS-stimulated cells. Mean±SEM, n=2–4.
interferon response since, in the two donors studied, IFIT1 expression was also upregulated by liposomes (Figure 6A). In 1°MDMs that were subsequently stimulated with LPS, this differences were less profound (Figure 6D), and so while this meant it is not technically meaningful to report the effect of inhibition on fold induction of effectors, it is possible to report some outcomes of this experiment with reasonable confidence, by examining only the data from LPS-stimulated cells, and using the liposome-treated cells as the control/comparator group.

Good dose-dependent knockdown of both miRNAs was achieved by this method (Figure 6C), with the maximum effect seen at a 200 nM oligonucleotide concentration. However, no effect of inhibiting the function of either miRNA could be seen on the production of TNF into cell culture supernatants or on TNF mRNA.

Raw data for all experiments are available

Discussion

This study revealed the primary response of the miRNA population in human 1°MDMs following exposure to LPS. The time periods chose were deliberately short in order to focus on primary rather than secondary effects; for instance the plethora of cytokines induced by activation of this inflammatory pathway also have potent cellular effects themselves. A key finding is that very few miRNAs are dynamically regulated within this time frame. No miRNAs decreased in abundance in any of the conditions tested, and IL-10 alone had no discernible effect on miRNA expression. Only five out of 197 expressed miRNAs showed a >1.5-fold change at any time point. Since it is thought that both hsa-miR-886-5p and hsa-miR-886-3p are fragments of Vault RNA, rather than true miRNAs, the number may be even lower.

Despite miR-155-3p undergoing the most dramatic change in expression level of any miRNA in the primary human MDMs, the absolute levels of this miRNA are the lowest of the miRNAs analysed. In resting cells, the abundance of miR-155-3p was close to the detection limit of the qPCR assays. However, for a short, transient period after LPS challenge the number of copies/cell of this miRNA become in the same order as resting levels of miR-155-5p. Furthermore miR-155-3p could be recovered from the RISC at this timepoint, suggesting that it may have biological function despite its low abundance.

The dynamic and differential regulation of miR-155-5p and miR-155-3p described herein in LPS/TLR4-stimulated macrophages was also observed during the TLR7 response in plasmacytoid dendritic cells, with similar kinetic and amplitude characteristics. The differential regulation of the miRNAs was ascribed to KH-type splicing regulatory protein (KHSRP). It is tempting to speculate that the dip in BIC seen at early timepoints in this study is due to accelerated processing of the -3p form from pri-miR-155 derived from existing transcripts although this needs additional study. Such regulation of the two mature miRs that can derive from the single pre-miR, so-called “arm switching/selection” is of increasingly intense research study. For instance, in a long time-course study of IFNγ activation of melanoma cells, 4 of the 10 highest regulated miRNAs were ‘star’ strands (miR-424-3p, miR-29b-1-5p, miR-27a-5p and miR23a-5p; current miRbase annotations), that were induced where the partner strands were not. Arm selection in miR-193a and miR-324 also play important roles in cancer. Mechanisms have remained elusive so far, although in at least one case this may be driven by temperature. Polta and colleagues identified three miRNAs, previously denoted as passenger strands (hsa-miR-92a-1-5p, hsa-miR-27b-5p, and hsa-miR-1260a), that had altered expression when the temperature varied between 32–39°C, and that together regulated the expression of PKCa.

Experiments with chemical inhibitors of different signalling pathways showed that, in line with the findings of others, the upregulation of miR-155-5p was reduced by IL-10, as well as by inhibition of the JNK/AP1 and NfκB pathways (in the latter case by inhibiting proteosomal degradation of IκBα with PSI). This explains the much lower induction of BIC in poly(I:C) treated cells since TLR3 is not functionally linked to NfκB activation in human 1°MDMs, hence the small induction might be JNK/AP1-dependent. ERK and p38 inhibition had no effect, again in line with previous findings. Interestingly, the relationship between BIC and miR-155-3p abundance was maintained during JNK and IL-10 treatment, but lost in the presence of PSI where NfκB activation resulted in a greater decrease in mature miRNA-155-3p than the BIC mRNA precursor. Since the kinetics of BIC and miR-155-3p abundance were in close agreement across all of the other experiments performed, this finding is difficult to reconcile. It is tempting to speculate that these cells have a decrease in miRNA processing in addition to lower levels of BIC transcription, leading to poor arm selection of miRNA-155-3p, although this would need further investigation. Finally, it is well established that CHX causes super-induction of LPS-dependent TNF mRNA, as is the case in the current work. The mechanism is not known; however, while it is possible that a similar mechanism operates for BIC, there is no evidence to support the need for de novo protein synthesis in the production of miR-155-3p.

In conclusion, this work provides a detailed description of the induction of miR-155-3p in human 1°MDMs and other myeloid cells by a range of inflammatory stimuli including LPS. At the peak of its abundance, miR-155-3p is transiently present at close to 1,000 copies/cell, the putative threshold for biological activity. This lends weight to the assertion that miR-155-3p is truly a miRNA, but that its transient induction complicates functional analysis. The limitations of the current study are the extremely low abundance of this miRNA in resting cells (which makes relative quantitation challenging), the wide range of the miR-155-3p response between individual donors, and the restrictions of performing complex, labour intensive assays in primary cells (which means that it is not always possible to generate all data points in all repeats). This also thwarted attempts that were made to assess changes in the abundance of a range of predicted target miRNAs for miR-155-3p (IFIT1, IFIT2, ZNF230, ZNF398, CDKN1B, MAPK13 and EIF2S1) following miRNA inhibition or overexpression. Unfortunately, no data from this
work can be reported with confidence due, in part, to technical limitations of working with an induced miRNA in primary MDMs that are exquisitely sensitive to PAMPs, and apparently also the liposomes used to transfect oligonucleotides into the cells.

Others have been more successful since a functional role for miR-155-3p is supported by a number of studies in which cellular targets have been described. In plasmacytoid dendritic cells and trophoblasts it plays a pro-inflammatory role, augmenting type I interferon expression by suppressing IRAK-M early after TLR7 activation of the cells\textsuperscript{9,11}. IRAK-M is a negative regulator of TLR signalling via Myd88 whose expression is restricted to myeloid cells\textsuperscript{41}, including the macrophages that were the focus of the current work. By restricting its expression transiently during the cell activation process via miR-155-3p, the inflammatory burst from the cells would be enhanced for a limited period. Conversely, miR-155-5p allows for dampening of the response over a longer time since one of its targets, TAB2, is part of the TAK1 complex that plays an important role in activating the IKK complex\textsuperscript{42}. Other reported targets include NKRAS and PTEN in trophoblasts\textsuperscript{11}, two Hsp40 genes (Dnaja2 and Dnajb1) controlling murine Th17 differentiation\textsuperscript{14}, MEF2C during cardiogenesis from embryonic stem cells\textsuperscript{43} and lymphoxygenin-beta (LT-β) a positive regulator of non-canonical NF-kB signalling in MCL where it has tumour suppressing properties\textsuperscript{16}.

Data availability
Underlying data
Microarray data (title: microRNA responses of LPS and IL-10 stimulated primary human monocyte-derived macrophages over a short time-course) are available at GEO: accession number GSE125572.

Open Science Framework: Transient up-regulation of miR-155-3p by lipopolysaccharide in primary human monocyte-derived macrophages results in RISC incorporation but does not alter TNF expression. https://doi.org/10.17605/OSF.IO/KUBCX\textsuperscript{22}.

The following underlying data files are available:

- Experiment 11_089 Effect of inhibitors on mRNA and miRNA.xlsx
- Experiment 11_005 Effect of inhibitors on mRNA and miRNA.xlsx
- Experiment 11_023 and 11_027 comparison of GM- vs M-CSF-differentiated macrophages.xlsx
- Experiment 11_031 AQ Absolute quantification of miRNAs.xlsx
- Experiment 11_055 Effect of inhibitors on mRNA and miRNA.xlsx
- Experiment 11_059 RIP of miRNAs and mRNAs.xlsx
- Experiment 11_083 RIP of msRNAs and mRNAs.xlsx
- Experiment 11_111 Effect of inhibitors on mRNA and miRNA.xlsx
- Experiment 5_125 delta delta Ct Timecourse of LPS induction with and without mycolactone or IL-10.xlsx
- Experiment 5_149 whole blot for Ago proteins with 2A8.tif
- Experiment 5_161 AQ and RQ RIP of miRNAs.xlsx
- Experiment 5_171 AQ and ddCt RIP of miRNAs.xlsx
- Experiment 5_181 Timcourse of miRNA and mRNA induction.xlsx
- Experiment 5_195 Induction of mRNA and miRNA by different TLR ligands.xlsx
- Experiment 5_199 mRNA and miRNA induction by LPS in monocytes vs macrophages.xlsx
- Experiments 5_155 & 5_161 whole blot for Ago proteins with 2A8.tif

Extended data
Open Science Framework: Transient up-regulation of miR-155-3p by lipopolysaccharide in primary human monocyte-derived macrophages results in RISC incorporation but does not alter TNF expression. https://doi.org/10.17605/OSF.IO/KUBCX\textsuperscript{22}.

The following extended data files are available:

- Experiment log showing the datasets used for each figure of the manuscript.xlsx
- List of miRNA expressed in primary human MDMs.xlsx
- Microarray data for the 197 expressed miRNAs.xlsx

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Grant information
This work was supported by grants from the Wellcome Trust (092744) and the Kennedy Institute Trustees.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements
I would like to acknowledge the late, great, Brian Foxwell of the Kennedy Institute of Rheumatology for his contribution to this work (conceptualisation, funding, supervision) and Professor Sir Marc Feldmann (Kennedy Institute of Rheumatology) who contributed to funding and review of the current manuscript.

I am grateful to Zissimos Mourelatos (University of Pennsylvania) for the kind gift of 2A8 ascites fluid, and to both Prof Pamela Small (University of Knoxville, Tennessee) and Prof Yoshito Kishi (Harvard University) for providing the mycolactone A/B used in these studies.
Open Peer Review

Current Peer Review Status: ? ? ?

Version 1

Reviewer Report 15 May 2019

https://doi.org/10.21956/wellcomeopenres.16435.r35299

© 2019 Bhattacharyya S et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Avijit Goswami
RNA Biology Research Laboratory, CSIR-Indian Institute of Chemical Biology, Kolkata, India
Suvendra N. Bhattacharyya
RNA Biology Research Laboratory, CSIR-Indian Institute of Chemical Biology, Kolkata, India

In this communication “Transient up-regulation of miR-155-3p by lipopolysaccharide in primary human monocyte-derived macrophages results in RISC incorporation but does not alter TNF expression”, the author tried to identify an unconventional miR-155-3p to be transiently upregulated during early hours of LPS stimulation in primary monocyte derived macrophages. The author reported only 5 miRNAs that happens to be upregulated during initial LPS treatment. It is quite commendable to observe the intent of the author to quantify the absolute number of miRNA copies/cell. miR-155-5p and miR-146a are the two very well-studied miRNAs that has been investigated in context to immune response. The role of miR-155-3p is yet to be substantiated along with identification of its targets. Some issues regarding this study have been discussed below.

1. miR-155-5p is the predominant strand that has been shown to have a copy number of around 1315±417 in resting phase and 9203±4216 during 24 hours of LPS stimulation. Copy number of miR-155-3p was shown for resting, 2 hours and 24 hours of LPS stimulation. Strangely, the author missed out mentioning the copy number of miR-155-5p at 2 hours of LPS treatment. Absolute quantification of miR-155-5p at 2 hours of LPS treated must be provided to comment on miR-155-3p as “most strongly upregulated miRNA at any timepoint”.
2. The author mentioned with reference from TargetScan Database miR-155-3p is designated as “not so confidently identified miRNA” due to its relatively low abundance of about 1000 copies/cell to be considered biologically functional. The author reported an average 750 copies of miR-155-3p per cell (which the author also considers as an issue). Can this be considered biologically functional? Even if there is a 400 fold increase in the number, it still doesn’t qualify for the 1000 copy cut off.
3. miR-155-5p has a profound effect having previously validated targets, can miR-155-3p shadow the effect of miR-155-5p?
4. Processing of pre-miR-155 and half-life of miR-155-3p could be another possible reason for increased number of miR-155-3p, the author should check the precursor level.
5. Even if there is RISC incorporation of miR-155-3p, the copy number is almost 100-times less than miR-155-5p.

Overall, although the idea is interesting, the abundance of miR-155-3p is a real concern.
Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Partly

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Regulation of miRNA activity in mammalian cells.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

---

**Author Response 06 Sep 2019**

**Rachel Simmonds**, Kennedy Institute of Rheumatology, London, UK

Thank you for taking the time to review my manuscript. As mentioned in the introduction, it reports historical data (several years past). While I agree that the additional experiments suggested would give greater insight to the data, there is no prospect of performing them as the lab where the work was done no longer exists (please see the acknowledgements). Hence this submission to WOR, whose unique approach of seeking to publish “results worth sharing” rather than complete stories has given a route to release the data and methodology within, that otherwise would have remained unpublished.

I have therefore modified the text to reflect your concerns and the additional/alternative approaches suggested, and have looked closely at the manuscript overall to ensure that the conclusions are not overstated on the basis of the available data.

miR-155-5p is the predominant strand that has been shown to have a copy number of around 1315±417 in resting phase and 9203±4216 during 24 hours of LPS stimulation. Copy number of miR-155-3p was shown for resting, 2 hours and 24 hours of LPS stimulation. Strangely, the author missed out mentioning the copy number of miR-155-5p at 2 hours of LPS treatment. Absolute quantification of miR-155-5p at 2 hours of LPS treated must be provided to comment on miR-155-3p as "most strongly upregulated miRNA at any timepoint".

This data is represented in Figure 4C, but I agree that only showing the 2 hours data for miR-155-3p in Table 3 was an omission. This has now been corrected.
The author mentioned with reference from TargetScan Database miR-155-3p is designated as “not so confidently identified miRNA” due to its relatively low abundance of about 1000 copies/cell to be considered biologically functional. The author reported an average 750 copies of miR-155-3p per cell (which the author also considers as an issue). Can this be considered biologically functional? Even if there is a 400 fold increase in the number, it still doesn’t qualify for the 1000 copy cut off. miR-155-5p has a profound effect having previously validated targets, can miR-155-3p shadow the effect of miR-155-5p?

Indeed, I complete agree with both these important points. Others have proposed and published functional roles for miR-155-3p based upon relative expression and without performing absolute quantification (sometimes based upon massive over-expression of miRNA by transfecting in miRNA mimics that would be present at far higher levels than upon cellular stimulation). Moreover, this quantification places miR-155-3p at the limit of biological function under only a time limited circumstance, albeit that the miRNA can be found within the RISC, and therefore potential of binding to and regulating targets. The new paragraph at the end of the discussion is intended to bring these issues out more clearly.

Processing of pre-miR-155 and half-life of miR-155-3p could be another possible reason for increased number of miR-155-3p, the author should check the precursor level.

I agree that analysing the abundance of the pre-miR-155 hairpin would be ideal, and I have looked again to see if this would be possible and concluded the following:

- No commercial suppliers make a validated assay for pre-miR-155
- Previous papers (eg O’Connell PNAS 2007) find that pre-miR-155 is barely detectable at any timepoint before or during LPS stimulation of BMDM by Northern blot
- Very few papers report quantifying pre-miR-155, and in all cases they use in-house SYBR-based PCR that cannot technically discriminate between pre-miR-155 and pri-miR-155 (PCR of the stemloop sequence would amplify both the pre-miR and pri-miR)
- In those papers that do directly compare pri-miR and pre-miR abundance for miR-155, they show that the assays give broadly comparable results (not surprising given the above)
- Other studies of miR-155-5p and -3p biogenesis (eg Zhou et al, Blood 2010, Ruggiero et al FEBS Lett 2019) also use pri-miR-155 assays to quantify the precursors, as I did.

Given that it is not possible to generate further samples for alternate approaches such as Northern blotting, I have made modifications to the results and discussion in light of the above. Furthermore, taking the approach of Zhou et al I have relabelled “BIC” as “pri-miR-155” in all figures and text, to clearly indicate the precursors that have been quantified.

Examining the half-life of miR-155-3p would also have been an interesting experiment, especially since miR-155-5p was recently shown to have a half-life of 10.5hrs (Marzi et al, Genome Res 2016 p554). Such notions of miRNA degradation and stability are only recently emerging and tackling this issue is out of the scope of the current manuscript. However, a discussion of this alternative explanation of the data is now given in the results and discussion.

As mentioned above, setting up additional experiments is not possible, hence the release of this data via Wellcome Open Research rather than a conventional publishing platform.

**Competing Interests:** No competing interests were disclosed.
Jochen Imig
Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland

The author uses an outdated microarray technology to characterize the miRNAs involved in primary immune responses to LPS in human monocyte derived macrophages (MDMs). Only a surprisingly small fraction of actively expressed miRNAs (5 of 197 out of a total 719 on the array) were induced at least 1.5 fold, with miR-155-3p being the strongest one. This stands in contrast to previous reports that the other dominant strand (5p) provided the biologically relevant miRNA. The bulk of the manuscript relies on in vitro simulations followed by time course analysis of relative and absolute expression of different readouts such as TNF, the BIC locus or the two miR-155 strands (5p and 3p). Although suppression of miR-155 had no effect on TNF levels, the author suggests that differential arm selection could play an important role in controlling immune responses. Lacking functional experiments, as well as no data to propose a mechanistic model, the author proposes a method for absolute quantification of miRNAs using oligo templates to generate a standard curve. Using this method, it is shown that A) absolute quantification of specific miRNAs is feasible and B) miR-155-5p levels exceed miR-155-3p by approximately an order of magnitude. The author should address a few points, as follows:

1. The microarray data should be validated with an orthogonal approach, such as a panel of selected miRNA (up- down-regulated and unchanged) by Taq-Man qRT-PCR or miRNA-Seq of at least 3 healthy individual donors to show the technical validity and reliability of the miRNA expression and candidate selection thereof.
2. No functional readouts are included for any of the experiments (for example, phagocytic activity or M1/M2 polarization) upon miR-155 OE or knockdown.
3. Although it is claimed that miR-155 is one of the most well-known miRNA involved in immune responses, the data in the paper suggests that at least in MDM, it does not play an important role in TNF secretion. This point needs further clarification.

Specific changes

Introduction - Paragraph 2
Should read “BIC knockout causes defects in germinal center formation and Ig class switching, leading to immunodeficiency”.

Methods

Inhibition of miRNAs
Last sentence needs rephrasing or clarification “since pilot experiments showed that extending the recovery time to significantly reduced the efficiency of inhibition below a meaningful level.”

Results

Figure 2C) Unclear why the author uses a crude extract of the toxin, when results from a pure synthetic version are already presented.
Figure 3C) This figure should read “Primary monocytes” instead of “Primary monocytes”. It is also unclear why the author chooses a different cytokine for MDM production.

Discussion
Being a sole author, it is understandable that there are physical limitations to the number of assays that can be performed on primary cells. But this is an obvious condition, making it unnecessary to reiterate it in the discussion section. The connection between miR-155 and immune activation in the model system used still remains unclear and needs further literature to support a model.

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: RNA Biology, long-non coding RNAs, Systems Biology, miRNAs, Epigenetics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Rachel Simmonds, Kennedy Institute of Rheumatology, London, UK

Thank you for taking the time to review my manuscript. As mentioned in the introduction, it reports historical data (several years past), and the “outdated” technology current at the time the experiment was performed. This submission to WOR, whose unique approach of seeking to publish “results worth sharing” rather than complete stories has given a route to release the data and methodology within, that otherwise would have remained unpublished.

The microarray data should be validated with an orthogonal approach, such as a panel of selected miRNA (up- down-regulated and unchanged) by Taq-Man qRT-PCR or miRNA-Seq of at least 3 healthy individual donors to show the technical validity and reliability of the miRNA expression and candidate selection thereof.

The manuscript already included orthogonal validation of two upregulated miRNAs (miR-155-5p and miR-155-3p). Two other upregulated miRNAs (miR-886-5p and -3p) were also validated but I prefer not to include this data in the manuscript as miR-886 is no longer in miRbase. No miRNAs were downregulated so there is no suitable miRNA to select in this instance.
Two unchanged miRNAs were also validated. First, miR-16-5p which was used as the comparator for the assays. Second, miR-146a-5p which was below the 1.5-fold cut-off in the microarray; validation of this unchanged miRNA is now included as Figure 1D. Therefore I believe the technical validity of the microarray is not in question.

No functional readouts are included for any of the experiments (for example, phagocytic activity or M1/M2 polarization) upon miR-155-3p OE or knockdown. Indeed, such experiments were not performed, so this data cannot be provided retrospectively. The work sought to examine the responses to the TLR4 signalling pathway rather than macrophage polarisation per se, that latter of which is achieved using combinations of stimuli/cytokines that were not used. TNF secretion was used as a positive control for TLR4 stimulation, and expected condition of the unstimulated cells (ie lacking in TNF secretion). This has been explained in the final paragraph of the introduction.

Although it is claimed that miR-155 is one of the most well-known miRNA involved in immune responses, the data in the paper suggests that at least in MDM, it does not play an important role in TNF secretion. This point needs further clarification. TNF secretion is only one aspect of the immune response, as laid out in the introduction other immune functions of miR-155 are in the adaptive immune system. Others (eg Kurowska-Stolarska et al PNAS 2011) have shown that miR-155-5p can modulate TNF secretion, however these authors studied longer timepoints (24hrs) than here. A discrepancy is perhaps not surprising given that miR-155-5p is much more highly expressed at this later timepoint, however these kinetic differences are out of the scope of the current manuscript that focussed on the primary response at early timepoints. This point has been emphasised in a new paragraph in the discussion.

Introduction - Paragraph 2 Should read "BIC knockout causes defects in germinal center formation and Ig class switching, leading to immunodeficiency".

Corrected

Methods, Inhibition of miRNAs; Last sentence needs rephrasing or clarification "since pilot experiments showed that extending the recovery time to significantly reduced the efficiency of inhibition below a meaningful level."

Rephrased

Results
Figure 2C) Unclear why the author uses a crude extract of the toxin, when results from a pure synthetic version are already presented. This finding may be of interest to the Buruli ulcer research community, where mycolactone is the pathogenic determinant of the extensive necrosis and immune suppression in that disease. Mycolactone purified from bacteria likely includes some natural variation in hydroxylation due to leakiness of the polyketide synthase machinery. I have therefore retained this data in the revised version.

Figure 3C) This figure should read “Primary monocytes” instead of “Primary monocytes”.

Typo corrected

Discussion; Being a sole author, it is understandable that there are physical limitations to the number of assays that can be performed on primary cells. But this is an obvious condition, making it unnecessary to reiterate it in the discussion section. The connection between miR-155 and
immune activation in the model system used still remains unclear and needs further literature to support a model.
The discussion now includes a concluding paragraph that places the work in context. As mentioned above, since the results being reported in the unique format of Wellcome Open Research do not include functional analysis; therefore I have been careful not to overstate the findings. Proposing a speculative model that isn't supported by the current data would fall into this category.

**Competing Interests:** No competing interests were disclosed.

RE Simmonds presents a study on the role of LPS on human monocyte-derived macrophages in the context of regulation of miRNA abundance. The author first analysed relative levels of miRNA during LPS stimulation by microarray technology. This resulted in identification of several miRNAs that were upregulated more than 1.5 fold upon LPS treatment. The most upregulated was miR-155-3p, derived from a pri-miR-155 (B cell integration cluster RNA - BIC). Absolute quantification of miR-155-3p, miR-155-5p and BIC showed intricate, time-dependent regulation of their abundance upon LPS stimulation. Intriguingly, other pathogen-associated molecular patterns also influenced miR-155-3p, miR-155-5p and BIC abundance but with various profiles. Finally, the author wanted to see if one of the predicted miR-155-3p target (TNF) was affected by the miR-155-5p or miR-155-3p inhibition. In general, it's an interesting study that shows fast and substantial response from the miRNAs to LPS stimulation. That said, few important controls are missing, the research into miRNA biogenesis is not adequately cited, some figure panels are not referenced in the text and most importantly there are other possible explanations for the observed phenotypes that have to be considered.

My specific comments are as follow:
1. Please expand the CD14 and MD2 abbreviations.
2. It would be good to provide GO term analysis of miR-155-5p and miR-155-3p predicated and validated targets. This might help to see a broader picture of what these miRNAs regulate in the context of innate immune response.
3. "...miR-155-3p was >100-fold induced at 2 hours, after which the levels began to reduce again (Figure 1D)..." I am pretty sure this is a reference to Figure 1E.
4. "...following exposure of macrophages to LPS were monitored alongside miR-155-5p and miR-155-3p in 10 human donors, taking a more detailed look at either early or later timepoints following stimulation (compiled data, Figure 1E)..." This is a reference to Figure 1F.
5. The main conclusion of the paper is that the biogenesis of miR-155-5p and miR-155-3p is altered during LPS stimulation. Unfortunately, there is no evidence for that. One possible way to get this information would be to perform in vitro pri-miRNA and pre-miRNA processing assays (before and after LPS stimulation). Also, one could analyse the levels of pre-miR-155 upon LPS stimulation. This could add additional layer of information about which biogenesis step (if any) is regulated.

6. There is another possible explanation for the observed phenotypes. It is possible that while miR-155-3p is upregulated in line with the BIC levels, the stability of miR-155-5p is compromised after LPS stimulation. To assay that, one would have to inhibit pol II (by actinomycin D) and trace the levels of miR-155-5p and miR-155-3p to calculate their half-life with and without LPS stimulation.

7. I don't understand the use of cycloheximide? I would rather see inhibition of pol II by actinomycin D (as described before) to see if the regulation of miR-155 is uncoupled from the regulation of transcription.

8. The reference to Figure 3D is missing.

9. The references to papers in miRNA biogenesis filed are completely missing. There is a mention of the KHSRP protein regulating miRNA biogenesis but no reference provided. My advice is to at least cite some recent comprehensive reviews on this subject (Treiber et al. 2019¹, Michlewski and Caceres 2019² and Creugny et al. 2018³).

10. The author reports that there were failed attempts to validate predicted mRNA targets for miR-155-3p function. This is a wrong approach. The focus should be on the proteins that these mRNAs code as the effects of miR-155-3p could be mostly visible at the level of protein translation.

References

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** microRNA biogenesis, RNA-binding proteins, innate immunity.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 06 Sep 2019

Rachel Simmonds, Kennedy Institute of Rheumatology, London, UK

Thank you for taking the time to review my manuscript. As mentioned in the introduction, it reports historical data (several years past). While I agree that the additional experiments suggested would give greater insight to the data, there is no prospect of performing them as the lab where the work was done no longer exists (please see the acknowledgements). Hence this submission to WOR, whose unique approach of seeking to publish “results worth sharing” rather than complete stories has given a route to release the data and methodology within, that otherwise would have remained unpublished.

I have therefore modified the text to reflect your concerns and the additional/alternative approaches suggested, and have looked closely at the manuscript overall to ensure that the conclusions are not overstated on the basis of the available data.

My specific comments are as follow:

Please expand the CD14 and MD2 abbreviations.

Expanded as requested

It would be good to provide GO term analysis of miR-155-5p and miR-155-3p predicated and validated targets. This might help to see a broader picture of what these miRNAs regulate in the context of innate immune response.

I have performed GO term analysis from miRDB predicted targets for miR-155-5p and miR-155-3p using the Panther over-representation test and the annotation dataset of Panther pathways. This is now presented as Figure 1H, and next text describes the pathways relevant to innate immunity. I’m not convinced that it’s terribly helpful. The recent and extensive review in original reference 6, Alivernini et al has focussed on the currently known validated targets, and I have included a more detailed description of the broader picture and cited this reference again at the end of the discussion.

"...miR-155-3p was >100-fold induced at 2 hours, after which the levels began to reduce again (Figure 1D)...." I am pretty sure this is a reference to Figure 1E.

"...following exposure of macrophages to LPS were monitored alongside miR-155-5p and miR-155-3p in 10 human donors, taking a more detailed look at either early or later timepoints following stimulation (compiled data, Figure 1E)..." This is a reference to Figure 1F.

My apologies for the mislabelling. This has been corrected, taking into account the addition of further validation data requested by another reviewer.

The main conclusion of the paper is that the biogenesis of miR-155-5p and miR-155-3p is altered during LPS stimulation. Unfortunately, there is no evidence for that. One possible way to get this
information would be to perform in vitro pri-miRNA and pre-miRNA processing assays (before and after LPS stimulation).

I was very careful to avoid making this conclusion, as I agree that further work would be needed to support such a contention. It is not the conclusion that was stated in the original abstract nor the discussion. However, in response to your comment I have reworded these to ensure that this cannot be misunderstood by other readers.

Also, one could analyse the levels of pre-miR-155 upon LPS stimulation. This could add additional layer of information about which biogenesis step (if any) is regulated.

I agree that analysing the abundance of the pre-miR-155 hairpin would be ideal, and I have looked again to see if this would be possible and concluded the following:

- No commercial suppliers make a validated assay for pre-miR-155
- Previous papers (eg O’Connell PNAS 2007) find that pre-miR-155 is barely detectable at any timepoint before or during LPS stimulation of BMDM by Northern blot
- Very few papers report quantifying pre-miR-155, and in all cases they use in-house SYBR-based PCR that cannot technically discriminate between pre-miR-155 and pri-miR-155 (PCR of the stemloop sequence would amplify both the pre-miR and pri-miR)
- In those papers that do directly compare pri-miR and pre-miR abundance for miR-155, they show that the assays give broadly comparable results (not surprising given the above)
- Other studies of miR-155-5p and -3p biogenesis (eg Zhou et al, Blood 2010, Ruggiero et al FEBS Lett 2019) also use pri-miR-155 assays to quantify the precursors, as I did.

Given that it is not possible to generate further samples for alternate approaches such as Northern blotting, I have made modifications to the results and discussion in light of the above. Furthermore, taking the approach of Zhou et al I have relabelled “BIC” as “pri-miR-155” in all figures and text, to clearly indicate the precursors that have been quantified.

There is another possible explanation for the observed phenotypes. It is possible that while miR-155-3p is upregulated in line with the BIC levels, the stability of miR-155-5p is compromised after LPS stimulation. To assay that, one would have to inhibit pol II (by actinomycin D) and trace the levels of miR-155-5p and miR-155-3p to calculate their half-life with and without LPS stimulation.

This would indeed be an interesting experiment, complicated by the fact that miR-155-5p itself is able to stabilise mRNA transcripts such as TNF (see Bala et al JBC 2011 p1436) and that miR-155-5p was recently shown to have a half-life of 10.5hrs (Marzi et al, Genome Res 2016 p554). Actinomycin D would surely have killed cells after this period of exposure, where such experiments usually run for a couple of hours at most. Such notions of miRNA degradation and stability are only recently emerging and tackling this issue is out of the scope of the current manuscript. However, a discussion of this alternative explanation of the data is now given in the results and discussion.

I don’t understand the use of cycloheximide? I would rather see inhibition of pol II by actinomycin D (as described before) to see if the regulation of miR-155 is uncoupled from the regulation of transcription.

As already mentioned in the text, cycloheximide is a standard test to separate out responses that required protein synthesis (secondary response) from that done (primary response). I have now clarified this in the introduction.

The reference to Figure 3D is missing.

Corrected
The references to papers in miRNA biogenesis filed are completely missing. There is a mention of the KHSRP protein regulating miRNA biogenesis but no reference provided. My advice is to at least cite some recent comprehensive reviews on this subject (Treiber et al. 2019, Michlewski and Caceres 2019 and Creugny et al. 2018).

*With respect, one of the references you provide (Creugney et al) was already cited (reference 1). I have included your review and the other reference as requested.*

The author reports that there were failed attempts to validate predicted mRNA targets for miR-155-3p function. This is a wrong approach. The focus should be on the proteins that these mRNAs code as the effects of miR-155-3p could be mostly visible at the level of protein translation. *Indeed, a variety of approaches are possible to achieve this, and several were used. The advantage of using mRNA rather than protein abundance is that it is possible to screen a larger number of potential candidates. Since miRNAs regulated both by inhibiting translation and by causing target mRNAs to be degraded this approach is acceptable. Never-the-less I have re-edited the discussion section to highlight different areas, and expand on the study limitations in response to all reviewer comments and the manuscript no longer refers to these failed attempts.*

**Competing Interests:** No competing interests were disclosed.